USA

The AI-powered guidance will focus on building sustainable habits related to diet, physical activity, recovery and sleep, helping individuals make informed lifestyle decisions in real time.

The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.

The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.

The approval expands Orzeyful’s commercial reach following its authorization in China in July 2026, marking another milestone in Takeda’s global launch strategy.

Under the agreement, Ono will work with Mediar to identify potential treatments using the biotechnology company’s fibrosis-focused discovery platform and expertise in myofibroblast biology and fibrosis-related pathways.

The team chemically synthesised nearly 300 of the AI-generated genomes and tested them in laboratory conditions, with sixteen of the resulting viruses proving viable.

Lilly disclosed the decision as part of its second-quarter results, removing a phase 1/2 study of LY3884961 in Gaucher disease type 1 (GD1) from its pipeline.

Moderna expects to make mFlusiva available in the U.S. ahead of the 2026-2027 respiratory virus season.

The newly raised capital will enable Inocras to expand its commercial operations and clinical infrastructure across the United States.

The company’s scientific capabilities include chimeric antigen receptor T-cell (CAR-T) therapies and treatments derived from induced pluripotent stem cells (iPSCs).